Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 10/30/25
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) CongressBusiness Wire • 10/15/25
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual MeetingBusiness Wire • 09/29/25
Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)Business Wire • 09/15/25
NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/10/25
2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street AnalystsThe Motley Fool • 08/29/25
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in SpainBusiness Wire • 08/25/25
NVCR Stock Slips Despite PMA Application to Treat Pancreatic CancerZacks Investment Research • 08/22/25
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic CancerBusiness Wire • 08/20/25
NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to SayZacks Investment Research • 07/24/25
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025Business Wire • 07/01/25
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 TrialZacks Investment Research • 06/06/25